BURLINGTON, VT, Vernal Biosciences, an innovative mRNA and LNP Contract Development and Manufacturing Organization announced the completion of a $20 million funding round.
The round was led by Ampersand Capital Partners and Charles River Labs with participation from Dynamk Capital and the Vermont Center for Emerging Technologies.
Vernal Biosciences, founded in 2021 and headquartered just outside of Burlington, Vermont, is a fully integrated Contract Development and Manufacturing Organization (CDMO) with a singular focus on manufacturing and formulating mRNA and LNP-mRNA. Because science matters more than ever, Vernal is inspired to accelerate the potential of mRNA through democratizing access to our expertise and unparalleled mRNA and LNP-mRNA platform technologies. Combined with Good Manufacturing Practices (cGMP) and control and quality systems, Vernal's technologies are an advanced manufacturing staging ground for research, preclinical, and ultimately clinical development supply needs.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about